Immune responses can involve rapid and extensive changes in immune cell function, and it has become clear that substantial alterations in cellular metabolism are required to support the activities of such cells 1 . Metabolic pathways can be configured to meet the particular demands of the cell for energy and/or biosynthesis (see Box 1). Cellular metabolism is emerging as a key factor in the control of immune responses 1, 2 . Natural killer (NK) cells are important effector lympho cytes that are best characterized for their antiviral and anticancer activities 3, 4 . They are potent producers of the cytokine IFNγ and can directly kill target cells through cytotoxic mechanisms. NK cell responses can be detected very rapidly after infection, and they have historically been considered as cells of the innate immune system. However, with the discovery of longlived NK cells and the demonstration of intrinsic innate immune memory, it is now appreciated that NK cells have roles spanning both innate and adaptive immune responses [5] [6] [7] [8] . NK cells can also have regulatory roles and can contribute to shaping T cell responses; depending on the context, NK cells can either stimulate or inhibit T cell responses (reviewed elsewhere 9 ). In this Review, we discuss what is currently known about the metabolic pathways used by NK cells and how cellular metabolism shapes NK cell responses.
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Metabolic pathways can be configured to meet the particular demands of the cell for energy and/or biosynthesis (see Box 1) . Cellular metabolism is emerging as a key factor in the control of immune responses 1, 2 . Natural killer (NK) cells are important effector lympho cytes that are best characterized for their antiviral and anticancer activities 3, 4 . They are potent producers of the cytokine IFNγ and can directly kill target cells through cytotoxic mechanisms. NK cell responses can be detected very rapidly after infection, and they have historically been considered as cells of the innate immune system. However, with the discovery of longlived NK cells and the demonstration of intrinsic innate immune memory, it is now appreciated that NK cells have roles spanning both innate and adaptive immune responses [5] [6] [7] [8] . NK cells can also have regulatory roles and can contribute to shaping T cell responses; depending on the context, NK cells can either stimulate or inhibit T cell responses (reviewed elsewhere 9 ) . In this Review, we discuss what is currently known about the metabolic pathways used by NK cells and how cellular metabolism shapes NK cell responses.
Metabolic responses in activated NK cells
As effectors of acute responses, NK cells are poised and ready to kill target cells and produce cytokines such as IFNγ rapidly upon activation. Resting mouse NK cells have low basal metabolic rates, maintaining low levels of glycolysis and oxidative phosphorylation (OXPHOS) 10, 11 . These low metabolic rates are sufficient to sustain acute NK cell responses, in terms of IFNγ production, and 4 hours of cytokine stimulation (with IL-15, with IL-12 plus IL-15 or with IL-12 plus IL-18) or 6 hours of receptor ligation (using anti-NK1.1 or anti-Ly49D) does not result in any increase in rates of glycolysis or OXPHOS 10 . However, these low rates of metabolism are important for the acute NK cell functions. Inhibition of OXPHOS or glycolysis significantly impaired IFNγ production at these short time points, albeit to varying degrees depending on the activation stimuli; receptor stimulation is much more sensitive to metabolic inhibition than cytokine stimulation is 10 .
It is now well accepted that NK cells have an important role in immune responses over prolonged periods, operating alongside the adaptive immune system. Interestingly, stimulation of NK cells for sustained periods results in robust metabolic changes that are required for NK cell effector functions. Overnight stimulation of mouse or human NK cells with various cytokine combinations results in substantial increases in the rates of both glycolysis and OXPHOS [11] [12] [13] [14] . These increased metabolic rates are facilitated by alterations in the metabolic machinery and the metabolic configurations of the activated NK cells. Activated NK cells increase glucose uptake and flux through glycolysis, which is supported by increased expression of glycolytic enzymes and associated nutrient transporters 12 . Increases in both basal OXPHOS rates and maximal respiratory capacity are accompanied by increased mitochondrial mass 15 . NK cells have been studied extensively in the context of infection using the mouse cytomegalovirus (MCMV) model. During the course of MCMV infection, NK cells undergo mitochondrial changes in vivo and have significantly increased mitochondrial mass at the peak of infection 16 . In human blood, there are two NK cell subsets that are distinguished on the basis of CD56 expression levels.
CD56
bright NK cells and CD56 dim NK cells produce large quantities of cytokines such as IFNγ in response to cytokine stimulation and receptor ligation, respectively. CD56 dim NK cells are important for immediate cytotoxic killing of target cells, whereas CD56 bright NK cells must upregulate the cytotoxic machinery before gaining cytotoxic potential. These two human NK cell subsets are also different in terms of various metabolic parameters. Stimulation with cytokines, including IL-2 and IL-12 plus IL-15, upregulates the expression of nutrient receptors, including the GLUT1 glucose transporter (also known as SLC2A1), amino acid transporters (SLC1A5 (also known as ASCT2), SLC7A5 and SLC3A2 (also known as CD98)) and the transferrin receptor (CD71), to a greater degree in CD56 bright NK cells than in CD56 dim NK cells, arguing for greater metabolic responses in the CD56 bright NK cells than in CD56 dim NK cells 13, 17 . Metabolic analysis of total NK cells from human blood shows that resting NK cells have relatively low rates of glycolysis and OXPHOS, which then increase significantly after overnight stimulation with IL-2 or IL-12 plus IL-15 (ref. 13 ). Interestingly, chronic exposure of human NK cells to IL-15 in vitro results in reduced metabolic rates 18 . Tissue-resident NK cells also increase the expression of nutrient receptors following stimulation, although the magnitude of these increases is less than it is for blood NK cells 19 . The importance of these metabolic changes for NK cell function has been investigated using various approaches to limit the flux through either glycolysis or OXPHOS. Strategies that reduce metabolic rates in mouse NK cells inhibit cytokine-induced proliferation and impair NK cell cytotoxicity against a range of cell lines in vitro 15, 20 . Concentrations of the metabolic inhibitors 2-deoxyglucose (2DG) and oligomycin that limit but do not completely inhibit glycolysis and OXPHOS, respectively, are found to inhibit the production of IFNγ and the expression of granzyme B by both mouse and human NK cells 12, 13 . 2DG treatment also decreases the ability of IL-15-activated human NK cells to kill K562 target cells 20 . Culturing NK cells in galactose, a fuel that can support only low rates of glycolysis, rather than glucose, also inhibits the effector function of both human and mouse NK cells 12, 13 . When 2DG is injected into mice, it is preferentially taken up by highly glycolytic cells and will limit the rate of glycolysis in these cells. 2DG treatment of mice following polyinosinic:polycytidylic acid (poly I:C) administration or MCMV infection results in reduced NK cell IFNγ production and, in the case of MCMV infection, reduced clearance of virally infected target cells and increased viral loads 12, 20 . In human NK cells, inhibition of amino acid uptake through SLC1A5 and SLC7A5 prevented IFNγ production and degranulation following antibody crosslinking of the activating receptor NKG2D 17 .
What fuels activated NK cells? Mouse NK cells activated by IL-2 and IL-12 metabolize glucose primarily to pyruvate and then lactate through aerobic glycolysis. Some pyruvate still enters the mitochondria, but this pyruvate is not metabolized through the tricarboxylic acid (TCA) cycle as is the case in other lymphocytes 15 . Instead, pyruvate is converted to mitochondrial citrate, which is metabolized by the citrate-malate shuttle (CMS) 15 ( fig. 1) . The CMS provides an alternative mode of generating NADH in the mitochondria to fuel OXPHOS and ATP synthesis via the export of mitochondrial citrate in exchange for cytosolic malate. The CMS also provides cytosolic NAD + , which is an important cofactor for the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), thus facilitating elevated rates of glycolysis 15 . Unlike the TCA cycle, which can receive inputs from multiple fuels (see Box 1) , the CMS is fuelled exclusively by glucose. Indeed, NK cells do not use glutamine as a fuel for driving OXPHOS; inhibition of glutaminase, the first enzyme in glutaminolysis, does not inhibit OXPHOS and does not affect NK cell effector functions 10, 21 . Whether NK cells use fatty acids as a fuel source has not been extensively studied, partly because there is a lack of specific tools for examining fatty acid oxidation. Etomoxir, which is an inhibitor commonly used to block Glucose is metabolized by glycolysis to pyruvate, which in turn can be used to fuel oxidative phosphorylation (oXPHoS) (see the figure) . Pyruvate is converted to acetylCoA in the mitochondria, which feeds into the tricarboxylic acid (TCA) cycle. The TCA cycle generates the reducing equivalents NADH and FADH 2 (not shown) that transfer electrons (e − ) to complex I and complex II of the electron transport chain (eTC), leading to a proton (H + ) gradient across the mitochondrial inner membrane that is used to drive the activity of ATP synthase (AS). Additional fuels can be used for OXPHOS and mitochondrial energy production. Fatty acids are broken down in the mitochondria through a process called β-oxidation that yields acetyl-CoA. Amino acids, most notably glutamine, can also be metabolized for the purposes of ATP production. Glutamine is metabolized via glutaminolysis to α-ketoglutarate (αKG) that can feed into the TCA cycle. In addition to fuelling ATP synthesis, glucose and glutamine can also be metabolized and used to support biosynthetic processes. Intermediates of glycolysis can be diverted into metabolic pathways to generate biosynthetic precursors that are important for the synthesis of lipids, nucleotides and proteins. Similarly, the TCA cycle intermediate citrate can be exported from the mitochondria and metabolized to support the biosynthesis of these molecules. Cells will metabolize glucose to lactate when there is no oxygen available for oXPHoS (anaerobic glycolysis, not shown). Cells with high biosynthetic demands will also metabolize glucose to lactate in the presence of oxygen (aerobic glycolysis) while also feeding pyruvate into the mitochondria to support oXPHoS. This metabolic configuration is of benefit because it allows for high flux through glycolysis, leading to elevated levels of glycolytic intermediates that can be diverted towards biosynthesis, while also generating large amounts of ATP. fatty acid oxidation, has recently been found to have a number of off-target effects [22] [23] [24] . However, the fact that etomoxir treatment had no effect on IFNγ production by receptor-activated or cytokine-activated NK cells suggests that fatty acids are not an important fuel for NK cells 10 . Interestingly, the accumulation of excess fatty acids within NK cells is found to be detrimental to NK cell metabolism and function 25 . Therefore, NK cells are primarily fuelled by glucose, which is metabolized by aerobic glycolysis in the cytosol and in the mitochondria via the CMS to drive OXPHOS and ATP production 15, 21 .
Metabolism during NK cell development
Metabolism has been best studied in mature NK cells, and no direct investigation of metabolism during NK cell development has been done. Developing murine NK cells undergo several stages of maturation in the bone marrow that can be identified on the basis of expression levels of CD11b and CD27 (ref. 26 ). Pre-NK cells (CD11b low CD27 hi ) undergo a burst of proliferation that correlates with expression of the amino acid transporter SLC3A2 and the transferrin receptor 11, 26 . 27 . For example, pre-NK cells express higher mRNA levels for the amino acid transporters Slc7a5 and Slc1a5, glycolytic enzymes including hexokinases Hexa and Hexb and phosphofructose kinase Pfkl, and enzymes involved in lipid synthesis such as fatty acid synthase (Fasn) and ATP citrate lyase (Acly). Therefore, the data suggest that, during NK cell development in the bone marrow, there is increased metabolic activity in pre-NK cells to support the demands placed on them by cellular proliferation.
NK cell education (also known as NK cell licencing) is a process for achieving functional maturation and self-tolerance. There is evidence that changes in cellular metabolism are associated with this NK cell education process. Educated human NK cells have been described to have increased expression of glucose transporters and elevated rates of glycolysis, but not of OXPHOS, compared with uneducated NK cells 28, 29 .
Regulation of NK cell metabolism
A number of key metabolic regulators have now been identified in NK cells. The mammalian target of rapamycin complex 1 (mTORC1) is well established as a regulator of various metabolic processes in diverse cell types. In NK cells, mTORC1 activity is important for normal mouse NK cell development and for activation-induced metabolic and functional responses in mature NK cells. mTORC1 activity is highest in CD11b low CD27
hi pre-NK cells and decreases as NK cells mature, which correlates with the expression pattern of nutrient transporters and metabolic enzymes 11, 27 . These data suggest that mTORC1 is important for increased metabolism in pre-NK cells to support proliferative expansion 11, 26 . Indeed, deletion of the mTOR kinase subunit or regulatory-associated protein of mTOR (raptor) specifically in CD11b low CD27 hi pre-NK cells (using Ncr1-Cre) resulted in a substantial block in NK cell differentiation in the bone marrow at the CD11b low -to-CD11b hi stage that was attributed to decreased pre-NK cell proliferation 11, 30 . While resting NK cells have low mTORC1 activity, cytokine stimulation induces robust increases in mTORC1 signalling in both human and mouse NK cells [11] [12] [13] 17 . Consistent with the increased metabolic readouts in CD56 bright NK cells, cytokine-induced mTORC1 signalling is much greater in CD56 bright NK cells than in CD56 dim NK cells 13, 17 . Activation of mouse NK cells in vitro or in vivo leads to increased mTORC1 activity, which is required for increased expression of nutrient transporters and glycolytic enzymes, for increased mitochondrial mass and for the expression of effector molecules including IFNγ and granzyme B [11] [12] [13] 
Maintaining NAD
+ in the cytosol is essential for glycolysis to continue, as it is an essential cofactor for the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Malate re-enters the mitochondria through SLC25A1, where it is converted back to oxaloacetate, yielding a second NADH molecule in the mitochondria. Oxaloacetate can then react with another glucose-derived acetyl-CoA to form another molecule of citrate, thus completing the cycle. In this way , the citrate-malate shuttle generates two molecules of NADH per molecule of pyruvate that enters the mitochondria, which feed into the electron transport chain (ETC) driving oxidative phosphorylation (OXPHOS) and ATP synthesis via ATP synthase (AS). By contrast, the tricarboxylic acid (TCA) cycle makes four molecules of NADH plus one molecule of FADH 2 (not shown). However, the citrate-malate shuttle has the additional output of cytosolic acetyl-CoA that can be used as the substrate for acetylation reactions or lipid synthesis.
rapamycin results in decreased glycolysis in mouse NK cells stimulated with either IL-2 plus IL-12 or high-dose IL-15 (refs 12,14 ). In mice treated with rapamycin during infection with MCMV, reduced mTORC1 activity in NK cells was associated with reduced NK cell proliferation, IFNγ production and cytotoxicity, leading to elevated viral burdens 31 . In human NK cells activated overnight with cytokines, mTORC1 activity is only required for increased NK cell metabolism in response to certain cytokine stimulations. IL-2-stimulated NK cells require mTORC1 activity for increased levels of glycolysis, whereas increased glycolysis in NK cells stimulated with IL-12 plus IL-15 is mTORC1 independent 13 . IFNγ production and SLC3A2 expression following ligation of the activating receptor NKG2D are also mTORC1 dependent 32 . The functions of the other mTOR complex in NK cells, mTOR complex 2 (mTORC2), are less well defined.
Unlike mTORC1, mTORC2 is not considered to be a major metabolic regulator. However, mTORC2 is important for mouse NK cell development and function and can impact NK cell metabolism because it negatively regulates the activity of mTORC1 (refs 30,33 ). mTORC2 limits mTORC1 activity by inhibiting signal transducer and activator of transcription 5 (STAT5)-mediated expression of the amino acid transporter SLC7A5 (ref.
33
). It is also worth noting that mTORC1 activity in mouse NK cells, and also in mouse CD8 + cytotoxic T lymphocytes (CTLs), is not downstream of the PI3K-AKT signalling axis but is acutely sensitive to the levels of the amino acids leucine and glutamine 21, 34, 35 (fig. 2) .
Two transcription factors have also been shown to be crucial for metabolic responses in cytokine-activated NK cells: sterol regulatory element-binding protein (SREBP) and MYC. SREBP is classically considered to be the master regulator of fatty acid and cholesterol synthesis, as it induces the expression of the majority of genes in these biosynthetic pathways 36 . Cytokines induce the activity of SREBP in mouse NK cells, and mTORC1 is required for maximal SREBP activity. However, SREBP-regulated fatty acid and cholesterol synthesis is not important for cytokine-induced responses in mouse NK cells; instead, a completely novel role for SREBP has been described. SREBP activity is essential for increased rates of glycolysis and OXPHOS in cytokine-stimulated NK cells because SREBP controls the expression of two of the key factors required for the CMS, the citrate-malate antiporter SLC25A1 and ACLY 15 . Therefore, SREBP controls the metabolic configuration engaged by NK cells (fig. 2) . Inhibition of SREBP activation using both pharmacological and genetic approaches results in a dramatic reduction in glycolysis and OXPHOS, impaired NK cell IFNγ production and reduced cytotoxicity against tumour cells both in vitro and in vivo 15 . SREBP transcription factors are also important for the effector functions of human NK cells; inhibition of SREBP activation results in impaired IFNγ production and decreased expression of effector molecules such as granzyme B 15 . MYC is required for the metabolism of activated NK cells because it controls the expression of the metabolic machinery in NK cells. MYC is required for the increased expression of glucose transporters and glycolytic enzymes to support glycolysis and for mitogenesis to provide the increased mitochondrial mass required to support high rates of OXPHOS 21 ( fig. 2) . Interestingly, in CD8 + CTLs, the transcription factor hypoxia-inducible factor 1α (HIF1α) is the key transcription factor required to support elevated glycolysis, but this is not the case in NK cells 21, 34 (for a comparison of NK and T cell metabolism, see TaBle 1 ). HIF1α-deficient mouse NK cells have normal levels of both glycolysis and OXPHOS in response to cytokine stimulation 21 . Although HIF1α does not appear to be important in this context, it might be predicted that HIF1α has a role in controlling NK cell metabolism in other contexts such as under conditions of hypoxia. MYC is often considered to be controlled downstream of mTORC1, but this is not necessarily the case in NK cells or indeed in CD8 + CTLs 21, 34, 35 . The initial upregulation of MYC expression in NK cells that occurs within minutes of IL-2 plus IL-12 stimulation is partially , MYC protein levels accumulate in a manner dependent on mammalian target of rapamycin complex 1 (mTORC1). mTORC1 is activated by IL-2 signalling and can increase MYC protein translation by promoting 5ʹ cap-dependent translation. Cytokine stimulation also induces the expression and activity of the amino acid transporter SLC7A5. At later time points following cytokine stimulation (hours), amino acid uptake through SLC7A5 is essential to sustain MYC protein levels, whereas mTORC1 activity is not required. Withdrawal of glutamine, which is exported through SLC7A5 to sustain SLC7A5-dependent amino acid import, or the direct inhibition of SLC7A5-mediated transport results in rapid loss of MYC protein expression within minutes. Although leucine uptake through SLC7A5 is required for mTORC1 activity at these later time points, leucine withdrawal is not sufficient to reduce MYC expression. Therefore, the uptake of other amino acids, such as methionine, phenylalanine, tyrosine, arginine or tryptophan, through SLC7A5 is important in the regulation of MYC. The activity of SREBP is greatly increased following stimulation with IL-2 plus IL-12 in mouse NK cells. Although mTORC1 is the key regulator of SREBP activation, other mechanisms also contribute to SREBP activity in cytokine-stimulated NK cells. MYC is important for the expression of the metabolic machinery in NK cells, and SREBP controls the metabolic configuration, namely , glucose metabolism through the citrate-malate shuttle.
dependent on mTORC1 activity, but MYC expression is completely independent of mTORC1 at all time points after a few hours. Instead, MYC expression depends on the availability of the amino acids that are required to maintain high rates of MYC translation to offset continuous MYC degradation 21 . Although glutamine is not an important fuel for NK cells (discussed above), glutamine is important for MYC signalling, as it facilitates amino acid uptake through the L-type amino acid transporter SLC7A5 ( fig. 2) 38 .
Metabolism and NK cell memory
It is now well accepted that NK cells have long-term functions, acting alongside the adaptive immune system, and can have features of immunological memory 7 . Depending on the context, these NK cells have been described as memory-like NK cells, trained NK cells or adaptive NK cells. Several studies have investigated whether metabolic processes are important in the formation and enhanced responses of these memory-like NK cells.
In mice, NK cells expressing the activating receptor Ly49H, which recognizes a MCMV-specific viral ligand m157, undergo clonal expansion in response to MCMV infection 6, 39 . This rapid proliferation leads to reduced mitochondrial fitness characterized by decreased mitochondrial membrane potential and increased levels of mitochondrial reactive oxygen species 16 . Following a contraction phase, these virus-specific NK cells persist for months as a self-renewing pool of memory-like NK cells with enhanced responsiveness upon reactivation 6 . An important process in the formation of these memorylike cells is restoring mitochondrial fitness, which is achieved by removing damaged mitochondria through autophagy, known as mitophagy 16 . Pharmacological approaches to induce autophagy during the peak of MCMV infection, such as inhibition of mTORC1 with rapamycin or activation of AMP-activated protein kinase (AMPK) with metformin, lead to increased numbers of memory NK cells 16 . Interestingly, similar roles have been described for mTORC1 and AMPK in the control of mouse CD8 + T cell memory [40] [41] [42] . In humans, infection with human cytomegalovirus (HCMV) results in long-term changes in a subset of NK cells, referred to in this instance as adaptive NK cells, that have distinct metabolism and functions that have been linked to epigenetic alterations [43] [44] [45] . In terms of function, adaptive NK cells in donors with HCMV seropositivity are less sensitive to innate cytokines, such as IL-12 and IL-18, but have increased responses through low-affinity Fcγ-receptor IIIA (FcγR3A; also known as CD16)-dependent recognition of antibody-coated target cells 43, 44 . FcγR3A crosslinking on adaptive NK cells induces greater mTORC1 activity than that on nonadaptive NK cells 46 . Adaptive NK cells also have altered metabolism, with increased mitochondrial mass and mitochondrial membrane potential along with higher rates of OXPHOS, compared with that of nonadaptive NK cells 45 . The chromatin-modifying transcriptional regulator AT-rich interactive domain-containing protein 5B (ARID5B) has been implicated in the control of enhanced mitochondrial metabolism in these adaptive NK cells 45 . Regulates mTORC1 and MYC 35, 96, 100 CTL , cytotoxic T lymphocyte; HIF1α, hypoxia-inducible factor 1α; mTORC1, mammalian target of rapamycin complex 1; NK cell, natural killer cell; OXPHOS, oxidative phosphorylation; SREBP, sterol regulatory element-binding protein; TCA , tricarboxylic acid; TCR , T cell receptor.
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NK cell memory-like responses have also been described in response to cytokine stimulation. Cytokineinduced memory-like mouse and human NK cells have increased levels of IFNγ production following restimulation and enhanced cytotoxicity towards tumour cells for periods from weeks to months following initial stimulation [47] [48] [49] [50] . Similarly, human NK cells stimulated through FcγR3A show memory-like attributes with increased cytotoxicity towards tumour cells 51 . However, the importance for NK cell metabolism in the generation of these memory-like NK cells or for the enhanced functionality of these cells is still to be determined.
Metabolism and NK cell dysfunction
There is accumulating evidence that impaired cellular metabolism is a crucial factor leading to dysfunctional NK cells in a range of chronic diseases such as obesity and cancer. Murine and human studies show that obesity impairs NK cell functional responses. The use of diet-induced obesity models or genetic obesity models, such as ob/ob mice, has shown that obese mice are more susceptible to mortality from infection with influenza virus, owing to lung inflammation. Splenic and lung NK cell numbers and cytotoxicity are substantially reduced in obese mice following infection compared with those in lean mice 52 . In obese mice, NK cells have impaired antitumour responses and fail to control tumour growth 25 . Humans with obesity, both children and adults, have reduced frequencies of circulating NK cells compared with their lean counterparts, and these NK cells are dysfunctional; they produce less IFNγ, express lower levels of granzyme B and perforin and have reduced cytotoxicity towards tumour target cells 25, [53] [54] [55] . Recent research has linked this NK cell dysfunction to impaired cellular metabolism 25, 55 . NK cells from obese mice or humans with obesity fail to engage a metabolic response when stimulated with cytokines and have substantially reduced metabolic rates compared with NK cells from lean mice or humans 25 . This metabolic dysfunction has been linked to peroxisome proliferatoractivated receptor (PPAR)-driven lipid accumulation in NK cells, leading to altered gene expression, the downregulation of MYC and mTORC1 signalling and decreased rates of glycolysis and OXPHOS 25 . NK cells from obese mice and humans with obesity fail to kill tumour cells, in part because they fail to correctly form a synapse with target cells; the cytotoxic machinery does not traffic to the NK cell-tumour cell synapse 25 . Indeed, there is evidence that the formation and maintenance of this NK cell-tumour cell synapse are energy-demanding processes 56, 57 . Human NK cells polarize mitochondria towards the NK cell-tumour cell synapse, and the NK cell mitochondrial membrane potential rapidly drops following target cell engagement, which is consistent with rapid energy use 57, 58 . Therefore, altered signalling and defective metabolism are key aspects of NK cell dysfunction in individuals with obesity.
A reduction in NK cell number and function has also been described in cancer, and altered NK cell metabolism is likely to be an important factor in this NK cell dysfunction 59, 60 . Tumour microenvironments are known to be metabolically restrictive and can contain very low concentrations of nutrients such as glucose, the key fuel for NK cells [61] [62] [63] [64] . Tumours can also contain high concentrations of lactate and a low pH, both of which can impair NK cell antitumour functions 65, 66 . Indeed, a recent human study showed that lactate produced by colorectal liver metastasis resulted in a decrease in the intracellular pH of tumour-infiltrating liver-resident NK cells, leading to mitochondrial dysfunction and apoptosis 67 . Additionally, a range of molecules that can actively repress NK cell metabolism are made within tumours. Elevated levels of transforming growth factor-β (TGFβ) are associated with various cancers 68, 69 , and TGFβ can directly repress NK cell metabolism through multiple mechanisms, including the inhibition of mTORC1 signalling 14, 70 ( fig. 3) . A recent study showed that tumours in the lungs can induce the expression of the gluconeogenesis enzyme fructose bisphosphatase 1 (FBP1) in tumour-infiltrating mouse NK cells through a mechanism possibly involving TGFβ 59 . FBP1 directly counteracts flux through glycolysis, and the study showed that pharmacological inhibition of FBP1 could achieve partial rescue of NK cell metabolism and effector functions 59 . Other molecules that can potentially repress NK cell metabolism include the oxysterols 25-hydroxycholesterol and 27-hydroxycholesterol, both of which inhibit the activation of SREBP transcription factors, which are key regulators of NK cell metabolism 15, 71, 72 (figs 2,3).
Cholesterol is converted to 27-hydroxycholesterol by the enzyme mitochondrial sterol 27-hydroxylase (CYP27A1), which is expressed in most tissues but at high levels in macrophages 73, 74 . Circulating levels of 27-hydroxycholesterol have been found to be elevated in patients with breast cancer 75 . Cholesterol is converted to 25-hydroxycholesterol by the enzyme cholesterol 25-hydroxylase, which is expressed at high levels by inflammatory macrophages and is also expressed by certain tumours including glioblastoma [76] [77] [78] . The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is often highly expressed in tumour cells or in tumour-associated cells such as tolerogenic dendritic cells 79, 80 . IDO1-mediated metabolism of tryptophan and the IDO1-derived metabolite l-kynurenine can inhibit human NK cell proliferation and cytotoxicity 81, 82 . The l-kynurenine transporter has recently been identified as SLC7A5, which is highly expressed on activated NK cells, suggesting that NK cells are susceptible to the inhibitory effects of l-kynurenine in tumours 21, 83 .
Targeting metabolism for immunotherapy Cellular immunotherapeutic strategies against solid tumours have been less successful than those against haematological cancers 84, 85 . Solid tumours suppress antitumour immune responses through multiple mecha nisms, including creating a metabolically restrictive microenvironment. To support high metabolic rates, tumour cells consume large quantities of fuels, including glucose and glutamine, which can lead to the depletion of these fuels from the tumour microenvironment [61] [62] [63] [64] [86] [87] [88] [89] . Understanding the metabolic requirements of activated NK cells will lead to strategies to modulate NK cells to function more effectively within this nutrient-restrictive tumour microenvironment. For instance, coordinated use of chemotherapy and/or radiotherapy may be an important mechanism to enhance NK cell antitumour responses. Inducing cell death pathways in a proportion of tumour cells will reduce the demand for glucose and therefore increase glucose levels in the tumour microenvironment, facilitating glycolysis and robust antitumour responses of adoptively transferred NK cells. CB-839, a drug targeting glutaminase, the first enzyme of glutaminolysis, is in multiple phase I clinical trials in patients with advanced solid tumours (NCT02861300 and NCT02071862). Inhibition of glutaminase does not inhibit NK cell-mediated antitumour functions, but this inhibitor will reduce glutamine consumption within tumours. Increased glutamine availability would support glycolytic metabolism in NK cells by sustaining MYC signalling 21 (see fig. 2 ). Inhibiting MYC degradation through the inhibition of glycogen synthase kinase 3 (GSK3) could be another strategy to sustain NK cell metabolism and function within the tumour microenvironment 21 . Indeed, GSK3 inhibitors have been shown to increase antitumour NK cell responses in multiple studies, although any link to cellular metabolism was not investigated 90, 91 . There are a number of cancer immunotherapies that involve engineering NK cells before adoptive transfer into patients. These include off-the-shelf strategies in which engineered NK cells are stored in cell banks ready for use 92 . For example, the NK cell line NK92 and engineered induced pluripotent stem cells are being developed for this purpose 93, 94 . Here, there is the possibility to also engineer NK cell metabolism to be resistant to the metabolically restrictive tumour microenvironment and to the molecules generated by tumours that can suppress NK cell metabolism and function ( fig. 3) .
Overall, it is now clear that cellular metabolism is crucial for the normal function of NK cells, and future research in this area is likely to reveal new and exciting therapeutic opportunities, although several key questions remain (Box 2).
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Box 2 | Important unanswered questions in relation to NK cell metabolism
• Why do activated natural killer (NK) cells use the citrate-malate shuttle rather than the tricarboxylic acid cycle to drive oxidative phosphorylation? • Although research has advanced our understanding of the metabolism of circulating NK cells from the blood and spleen, nothing is known about the metabolic pathways used by tissue-resident NK cells and the impact cellular metabolism has on their function.
• NK cell metabolism has largely been studied in vitro. It will be important to investigate NK cell metabolism in vivo, especially in immune microenvironments where levels of nutrients may be limiting.
• In CD8 + T cells, there is plasticity with metabolic pathways; under conditions of glucose limitation, T cells adapt and use more glutamine. It will be interesting to determine how NK cell metabolic pathways adapt to metabolically restrictive environments.
• Can NK cell metabolism be modulated to provide more robust NK cell-based immunotherapy? • Are metabolic alterations important for NK cell memory-like responses?
